Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5419]
News [12581]
Articles [170]
Editorials [5]
Conferences [246]
elearning [17]
MicroDicer and MicroGrater make quick work of tumour dissection
MicroDicer and MicroGrater make quick work of tumour dissection
WCLC 2024: Osimertinib with savolitinib demonstrates stronger efficacy than osimertinib alone in patients who do not respond well to EGFR-TKIs therapy
WCLC 2024: Osimertinib with savolitinib demonstrates stronger efficacy than osimertinib alone in patients who do...
Chemical screen identifies PRMT5 as therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer
Chemical screen identifies PRMT5 as therapeutic vulnerability for paclitaxel-resistant triple-negative breast...
WCLC 2024: Zongertinib demonstrates promising efficacy in patients with HER2-mutant NSCLC: Primary phase Ib analysis of beamion LUNG-1
WCLC 2024: Zongertinib demonstrates promising efficacy in patients with HER2-mutant NSCLC: Primary phase Ib...
WCLC 2024: Breakthrough therapy BAY 2927088 demonstrates ‘rapid, substantial and durable responses’ in patients with HER2-mutant NSCLC
WCLC 2024: Breakthrough therapy BAY 2927088 demonstrates ‘rapid, substantial and durable responses’ in patients...
“Draw me a cell”: Generative AI takes on clinical predictions in cancer
“Draw me a cell”: Generative AI takes on clinical predictions in cancer
WCLC 2024: Results from the FURTHER trial demonstrate firmonertinib is a promising potential therapy for patients with NSCLC with EGFR PACC mutations
WCLC 2024: Results from the FURTHER trial demonstrate firmonertinib is a promising potential therapy for patients...
How the scars of demolished brain tumours seed relapse
How the scars of demolished brain tumours seed relapse
WCLC 2024: Amivantamab-vmjw plus lazertinib show strong favourable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
WCLC 2024: Amivantamab-vmjw plus lazertinib show strong favourable overall survival trend versus osimertinib in...
Age-related changes in male fibroblasts increase treatment-resistant melanoma
Age-related changes in male fibroblasts increase treatment-resistant melanoma

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation